Total
0
Shares
Immutep (IMM) - Executive Director and CEO, Marc Voigt
Executive Director and CEO, Marc Voigt
Source: Immutep
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Biotechnology company Immutep (IMM) closes its share purchase plan (SPP) which is oversubscribed by more than $2 million
  • Following strong demand from shareholders, Immutep has increased the size of the SPP to accept the full amount of applications
  • Money raised from the SPP and a recent $60 million placement will go towards ongoing immune-oncology clinical development programs, a pre-clinical autoimmune disease program and general working capital
  • The company says it expects the 13,799,149 new shares will be issued on July 23 and will commence trading on the ASX on July 26
  • Immutep is up 1.5 per cent, trading at 50.8 cents at 12:45 pm AEST
Biotechnology company Immutep (IMM) has closed its share purchase plan oversubscribed by more than $2 million. The share purchase plan closed on Monday 19 July after receiving total application funds of $7,175,720, exceeding its targeted amount of $5 million. Following the strong demand from shareholders, Immutep has agreed to increase the size of the SPP to accept the full number of applications. The funds come in addition to a recent $60 million two-tranche institutional placement. However the second tranche of around $46.3 million is still subject to shareholder approval. Immutep says the money raised from both the SPP and placement will go towards ongoing immune-oncology clinical development programs, its pre-clinical program in autoimmune disease and general working capital. The company has been working on immunotherapeutic products for the treatment of cancer and autoimmune disease, particularly its lead product candidate, eftilagimod alpha, a soluble LAG-3 protein. The company said it expected the 13,799,149 new shares under the SPP to be issued on July 23, 2021, and would commence trading on the ASX on July 26. Immutep was up 1.5 per cent, trading at 50.8 cents at 12:45 pm AEST.
IMM by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.